A week ago, drug companies announced that their vaccine had been shown to be effective against the UK variant. Now that of South Africa is also added, although with differences, since it has shown a slightly lower neutralization of the virus.

The American company Moderna said that laboratory studies indicated that its vaccine for Covid-19 would continue to protect against the variants of the coronavirus identified in South Africa, but «as a precaution» they will develop a booster of the formula against mutations.

The analysis found in South Africa a six-fold reduction in antibody levels with the B.1.351 variant first observed in South Africa, but the levels are believed to remain above what is required for protection against Covid -19.


Flexible technology

Previously, the technicians have explained that the formulas developed by mRNA technology are easy to modify if considered necessary, although they need a new approval by the health authorities.

This flexibility includes the ability to alter the RNA sequence in the vaccine to offer protection against additional strains of the virus, should adjustments need to be made.

“Out of abundance of caution and taking advantage of the flexibility of our mRNA platform, we are advancing an emerging variant boost candidate against the variant first identified in South Africa in the clinic to determine if it will be more effective in boosting titers against it and potentially future variants ”.